Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Cytokeratin 8 Level in Age-related Macular Degeneration
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT02707575
- Locations
- 🇰🇷
Inje University Ilsan Paik Hospital, Goyang, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Seoul, Korea, Republic of
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 229
- Registration Number
- NCT02699450
- Locations
- 🇺🇸
United Med Res Inst, Inglewood, California, United States
🇺🇸Ophthalmic Clinical Trials San Diego, Oceanside, California, United States
🇺🇸Southern CA Desert Retina Cons, Palm Desert, California, United States
A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02698566
- Locations
- 🇺🇸
Southeastern Retina Associates, Chattanooga, Tennessee, United States
🇺🇸Char Eye Ear &Throat Assoc, Charlotte, North Carolina, United States
🇺🇸Paducah Retinal Center, Paducah, Kentucky, United States
Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Prof. Dr. Antonia M. Joussen
- Target Recruit Count
- 4
- Registration Number
- NCT02665689
- Locations
- 🇩🇪
Department of Ophthalmology, Charite, Berlin, Berlin, Germany
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Instituto de Olhos de Goiania
- Target Recruit Count
- 20
- Registration Number
- NCT02646670
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT02647515
Rainbow Extension Study
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT02640664
- Locations
- 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Instituto de Olhos de Goiania
- Target Recruit Count
- 2
- Registration Number
- NCT02641457
- Locations
- 🇧🇷
Instituto de Olhos de Goiania, Goiania, GO, Brazil
CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab
- Conditions
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02634970
Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02614937
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.